Gene Expression and Attention Lapses with a Countermeasure for Sleep Loss [Presentation]

Details

• Creators:
  Uyhelji, Hilary A ; Munster, Susan K. ; White, Vicky ; Nicholson, Scott J.
• Corporate Creators:
  United States. Department of Transportation. Federal Aviation Administration. Civil Aerospace Medical Institute
• Subject/TRT Terms:
  • Air transportation
  • Aviation safety
  • Behavior
  • Cognitive impairment
  • Fatigue (Physiological condition)
  • Human subject testing
  • Neurology
  • Sleep
  • Sleep deprivation Impairment
  • Modafinil
• DOI:
  https://doi.org/10.21949/1529670
• Resource Type:
  Presentations
• Geographical Coverage:
  United States
• Corporate Publisher:
  United States. Department of Transportation. Federal Aviation Administration. Office of Aviation. Civil Aerospace Medical Institute
• Abstract:
  Sleep disruption presents a substantial risk to health and safety, particularly due to the risks of performance degradation in safety-critical operations that can result in catastrophic injuries or mortality. Federal regulations exist to minimize the risks of fatigue with limitations on hours worked and requirements for fatigue risk management plans. Yet, even with workload controls and scheduled opportunities for rest, fatigue may be caused by factors such as personal and lifestyle choices, illness, and circadian disruption from travel across multiple time zones. Complicating risk mitigation is the challenge of identifying and measuring fatigue. Here, we report on gene expression biomarkers (biological indicators) for cognitive impairment during sleep loss.
• Format:
  PDF
• Download URL:
  https://rosap.ntl.bts.gov/view/dot/75223/dot_75223_DS1.pdf
• File Type:
  [PDF - 939.94 KB]
• Collection(s):
  FAA Civil Aerospace Medical Institute
• Main Document Checksum:
  urn:sha-512:8842d2c257454e1c8a893b8249cab700ce8e769f81d4c960470c8365b57640ed02c7cedd31c58ac06a6b8cae187a491ef4d9f604ec8d24d0fee254ff2b98dda6